title: The selective metabotropic glutamate 2/3 receptor agonist MGS0028 reverses psychomotor abnormalities and recognition memory deficits in mice lacking the pituitary adenylate cyclase-activating polypeptide.
abstract: Previous studies suggest that metabotropic glutamate 2/3 receptors are involved in psychiatric disorders. In this study, we examined the effects of the selective metabotropic glutamate 2/3 (mGlu2/3) receptor agonist MGS0028 on behavioral abnormalities in mice lacking the pituitary adenylate cyclase-activating polypeptide (PACAP), an experimental model of psychiatric disorders such as schizophrenia and attention-deficit/hyperactivity disorder. We found that PACAP-deficient mice showed impairments in the novel object recognition test and these impairments were improved by MGS0028 (0.1 mg/kg). Similarly, MGS0028 improved hyperactivity and jumping behaviors, but did not reverse increased immobility times in the forced swim test in PACAP-deficient mice. These results suggest that MGS0028 may be a potential, novel treatment for psychiatric disorders.
authors.affiliation: Japan Society for the Promotion of Science, Tokyo, Japan.
authors.forename: Yukio
authors.initials: Y
authors.lastname: Ago
authors.forename: Naoki
authors.initials: N
authors.lastname: Hiramatsu
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Ishihama
authors.forename: Keisuke
authors.initials: K
authors.lastname: Hazama
authors.forename: Atsuko
authors.initials: A
authors.lastname: Hayata-Takano
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Shibasaki
authors.forename: Norihito
authors.initials: N
authors.lastname: Shintani
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Hashimoto
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Kawasaki
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Onoe
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Chaki
authors.forename: Atsuro
authors.initials: A
authors.lastname: Nakazato
authors.forename: Akemichi
authors.initials: A
authors.lastname: Baba
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Takuma
authors.forename: Toshio
authors.initials: T
authors.lastname: Matsuda
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000378:metabolism; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D001643:Bridged Bicyclo Compounds / Q000627:therapeutic use*; D003998:Dicarboxylic Acids / Q000627:therapeutic use*; D004195:Disease Models, Animal; D008297:Male; D008569:Memory Disorders / Q000188:drug therapy* / Q000378:metabolism; D051379:Mice; D008817:Mice, Mutant Strains; D058990:Molecular Targeted Therapy; D009419:Nerve Tissue Proteins / Q000819:agonists / Q000378:metabolism; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D018697:Nootropic Agents / Q000627:therapeutic use*; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide / Q000235:genetics / Q000378:metabolism*; D018094:Receptors, Metabotropic Glutamate / Q000819:agonists* / Q000378:metabolism; D021641:Recognition, Psychology / Q000187:drug effects
chemical_list: C495402:Adcyap1 protein, mouse; D014150:Antipsychotic Agents; D001643:Bridged Bicyclo Compounds; D003998:Dicarboxylic Acids; D009419:Nerve Tissue Proteins; D018697:Nootropic Agents; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D018094:Receptors, Metabotropic Glutamate; C108822:metabotropic glutamate receptor 2; C102718:metabotropic glutamate receptor 3; C418124:MGS 0028